Interim Results of a Phase I/II Clinical Study to Assess the Safety And Efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-TATE Produced by the N.N. Blokhin National Medical Research Center of Oncology in Patients with Neuroendocrine Neoplasia

Introduction : Peptide-receptor radionuclide therapy (PRRT) is currently a well-studied treatment option for patients with neuroendocrine tumors. Based on the results of the Phase III NETTER-1 and NETTER-2 trials, 177 Lu-DOTA-TATE therapy has become the standard for second- and subsequent-line therapy. However, there are currently no domestic studies investigating PRRT. In our study, we evaluated the efficacy and safety of 177 Lu-DOTA-TATE, a radiopharmaceutical drug synthesized in the cyclotron-radiochemistry laboratory of the Department of Radionuclide Diagnostics and Therapy at the N.N. Blokhin National Medical Research Center of Oncology and having undergone preclinical trials, in patients with neuroendocrine neoplasias (NENs). Materials and Methods : This phase I/II study enrolled patients with metastatic NENs of various locations with Ki-67